Pediatric Gastroenterology, Hepatology & Nutrition

  • 제23권5호
  • /
  • Pages.411-422
  • /
  • 2020
  • /
  • 2234-8646(pISSN)
  • /
  • 2234-8840(eISSN)
대한소아소화기영양학회 (The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition)
권호 표지
DOI QR코드

DOI QR Code

Very Early-Onset Inflammatory Bowel Disease: A Challenging Field for Pediatric Gastroenterologists

  • Arai, Katsuhiro (Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development)
  • 투고 : 2019.12.26
  • 심사 : 2020.06.02
  • 발행 : 2020.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

With the increasing number of children with inflammatory bowel disease (IBD), very early-onset IBD (VEO-IBD), defined as IBD that is diagnosed or that develops before 6 years of age, has become a field of innovation among pediatric gastroenterologists. Advances in genetic testing have enabled the diagnosis of IBD caused by gene mutations, also known as monogenic or Mendelian disorder-associated IBD (MD-IBD), with approximately 60 causative genes reported to date. The diagnosis of VEO-IBD requires endoscopic and histological evaluations. However, satisfactory small bowel imaging studies may not be feasible in this small population. Both genetic and immunological approaches are necessary for the diagnosis of MD-IBD, which can differ among countries according to the available resources. As a result of the use of targeted gene panels covered by the national health insurance and the nationwide research project investigating inborn errors of immunity, an efficient approach for the diagnosis of MD-IBD has been developed in Japan. Proper management of VEO-IBD by pediatric gastroenterologists constitutes a challenge. Some MD-IBDs can be curable by allogenic hematopoietic stem cell transplantation. With an understanding of the affected gene functions, targeted therapies are being developed. Social and psychological support systems for both children and their families should also be provided to improve their quality of life. Multidisciplinary team care would contribute to early diagnosis, proper therapeutic interventions, and improved quality of life in patients and their families.

키워드

참고문헌

  1. Benchimol EI, Bernstein CN, Bitton A, Carroll MW, Singh H, Otley AR, et al. Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases. Am J Gastroenterol 2017;112:1120-34. https://doi.org/10.1038/ajg.2017.97
  2. Benchimol EI, Mack DR, Nguyen GC, Snapper SB, Li W, Mojaverian N, et al. Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. Gastroenterology 2014;147:803-13.e7; quiz e14-5. https://doi.org/10.1053/j.gastro.2014.06.023
  3. El Mouzan MI, Saadah O, Al-Saleem K, Al Edreesi M, Hasosah M, Alanazi A, et al. Incidence of pediatric inflammatory bowel disease in Saudi Arabia: a multicenter national study. Inflamm Bowel Dis 2014;20:1085-90.
  4. Ishige T, Tomomasa T, Hatori R, Tatsuki M, Igarashi Y, Sekine K, et al. Temporal trend of pediatric inflammatory bowel disease: analysis of national registry data 2004 to 2013 in Japan. J Pediatr Gastroenterol Nutr 2017;65:e80-2. https://doi.org/10.1097/MPG.0000000000001547
  5. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011;17:423-39. https://doi.org/10.1002/ibd.21349
  6. Chouraki V, Savoye G, Dauchet L, Vernier-Massouille G, Dupas JL, Merle V, et al. The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007). Aliment Pharmacol Ther 2011;33:1133-42. https://doi.org/10.1111/j.1365-2036.2011.04628.x
  7. Ong C, Aw MM, Liwanag MJ, Quak SH, Phua KB. Rapid rise in the incidence and clinical characteristics of pediatric inflammatory bowel disease in a South-East Asian cohort in Singapore, 1994-2015. J Dig Dis 2018;19:395-403. https://doi.org/10.1111/1751-2980.12641
  8. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018;390:2769-78. https://doi.org/10.1016/S0140-6736(17)32448-0
  9. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl A:5A-36A. https://doi.org/10.1155/2005/269076
  10. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314-21. https://doi.org/10.1002/ibd.21493
  11. Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014;147:990-1007.e3. https://doi.org/10.1053/j.gastro.2014.07.023
  12. Turpin W, Goethel A, Bedrani L, Croitoru Mdcm K. Determinants of IBD heritability: genes, bugs, and more. Inflamm Bowel Dis 2018;24:1133-48. https://doi.org/10.1093/ibd/izy085
  13. Uhlig HH, Powrie F. Translating immunology into therapeutic concepts for inflammatory bowel disease. Annu Rev Immunol 2018;36:755-81. https://doi.org/10.1146/annurev-immunol-042617-053055
  14. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009;361:2033-45. https://doi.org/10.1056/NEJMoa0907206
  15. Shim JO. Recent advance in very early onset inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr 2019;22:41-9. https://doi.org/10.5223/pghn.2019.22.1.41
  16. Ouahed J, Spencer E, Kotlarz D, Shouval DS, Kowalik M, Peng K, et al. Very early onset inflammatory bowel disease: a clinical approach with a focus on the role of genetics and underlying immune deficiencies. Inflamm Bowel Dis 2020;26:820-42. https://doi.org/10.1093/ibd/izz259
  17. Benchimol EI, Manuel DG, Guttmann A, Nguyen GC, Mojaverian N, Quach P, et al. Changing age demographics of inflammatory bowel disease in Ontario, Canada: a population-based cohort study of epidemiology trends. Inflamm Bowel Dis 2014;20:1761-9. https://doi.org/10.1097/MIB.0000000000000103
  18. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17. https://doi.org/10.1053/j.gastro.2004.01.063
  19. Heyman MB, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005;146:35-40. https://doi.org/10.1016/j.jpeds.2004.08.043
  20. Bequet E, Sarter H, Fumery M, Vasseur F, Armengol-Debeir L, Pariente B, et al. Incidence and phenotype at diagnosis of very-early-onset compared with later-onset paediatric inflammatory bowel disease: a population-based study [1988-2011]. J Crohn's Colitis 2017;11:519-26.
  21. Takeuchi I, Kaburaki Y, Arai K, Shimizu H, Hirano Y, Nagata S, et al. Infliximab for very early-onset inflammatory bowel disease: a tertiary center experience in Japan. J Gastroenterol Hepatol 2020;35:593-600. https://doi.org/10.1111/jgh.14836
  22. Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet 2016;48:67-73. https://doi.org/10.1038/ng.3459
  23. Kadowaki T, Ohnishi H, Kawamoto N, Hori T, Nishimura K, Kobayashi C, et al. Haploinsufficiency of A20 causes autoinflammatory and autoimmune disorders. J Allergy Clin Immunol 142018;141:1485-8.e11. https://doi.org/10.1016/j.jaci.2017.10.039
  24. Umeno J, Hisamatsu T, Esaki M, Hirano A, Kubokura N, Asano K, et al. A hereditary enteropathy caused by mutations in the SLCO2A1 gene, encoding a prostaglandin transporter. PLoS Genet 2015;11:e1005581. https://doi.org/10.1371/journal.pgen.1005581
  25. Kelsen JR, Sullivan KE, Rabizadeh S, Singh N, Snapper S, Elkadri A, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the evaluation and management for patients with very early-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2020;70:389-403. https://doi.org/10.1097/mpg.0000000000002567
  26. Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014;58:795-806. https://doi.org/10.1097/mpg.0000000000000239
  27. Watson TA, Petit P, Augdal TA, Avni EF, Bruno C, Damasio MB, et al. European Society of Paediatric Radiology abdominal imaging task force: statement on imaging in very early onset inflammatory bowel disease. Pediatr Radiol 2019;49:841-8. https://doi.org/10.1007/s00247-019-04375-8
  28. Nambu R, Hagiwara SI, Kakuta F, Hara T, Shimizu H, Abukawa D, et al. Current role of colonoscopy in infants and young children: a multicenter study. BMC Gastroenterol 2019;19:149. https://doi.org/10.1186/s12876-019-1060-7
  29. Obayashi N, Arai K, Nakano N, Mizukami T, Kawai T, Yamamoto S, et al. Leopard skin-like colonic mucosa: a novel endoscopic finding of chronic granulomatous disease-associated colitis. J Pediatr Gastroenterol Nutr 2016;62:56-9. https://doi.org/10.1097/MPG.0000000000000905
  30. Conrad MA, Carreon CK, Dawany N, Russo P, Kelsen JR. Distinct histopathological features at diagnosis of very early onset inflammatory bowel disease. J Crohn's Colitis 2019;13:615-25. https://doi.org/10.1093/ecco-jcc/jjy212
  31. Iwama I, Shimizu H, Nambu R, Okuhira T, Kakuta F, Tachibana N, et al. Efficacy and safety of a capsule endoscope delivery device in children. Eur J Gastroenterol Hepatol 2019;31:1502-7. https://doi.org/10.1097/MEG.0000000000001513
  32. Oikawa-Kawamoto M, Sogo T, Yamaguchi T, Tsunoda T, Kondo T, Komatsu H, et al. Safety and utility of capsule endoscopy for infants and young children. World J Gastroenterol 2013;19:8342-8. https://doi.org/10.3748/wjg.v19.i45.8342
  33. Yokoyama K, Yano T, Kumagai H, Mizuta K, Ono S, Imagawa T, et al. Double-balloon enteroscopy for pediatric patients: evaluation of safety and efficacy in 257 cases. J Pediatr Gastroenterol Nutr 2016;63:34-40. https://doi.org/10.1097/MPG.0000000000001048
  34. Hagiwara SI, Kudo T, Kakuta F, Inoue M, Yokoyama K, Umetsu S, et al. Clinical safety and utility of pediatric balloon-assisted enteroscopy: a multicenter prospective study in Japan. J Pediatr Gastroenterol Nutr 2019;68:306-10. https://doi.org/10.1097/MPG.0000000000002181
  35. Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohn's Colitis 2014;8:1179-207. https://doi.org/10.1016/j.crohns.2014.04.005
  36. Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. https://doi.org/10.1097/MPG.0000000000002035
  37. Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:292-310. https://doi.org/10.1097/MPG.0000000000002036
  38. Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology 2017;152:1901-14.e3. https://doi.org/10.1053/j.gastro.2017.02.004
  39. Grossman AB, Noble AJ, Mamula P, Baldassano RN. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. Inflamm Bowel Dis 2008;14:750-5. https://doi.org/10.1002/ibd.20387
  40. Kakuta Y, Kawai Y, Okamoto D, Takagawa T, Ikeya K, Sakuraba H, et al. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol 2018;53:1065-78. https://doi.org/10.1007/s00535-018-1486-7
  41. Kakuta Y, Kinouchi Y, Shimosegawa T. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping. J Gastroenterol 2018;53:172-80. https://doi.org/10.1007/s00535-017-1416-0
  42. Kelsen JR, Grossman AB, Pauly-Hubbard H, Gupta K, Baldassano RN, Mamula P. Infliximab therapy in pediatric patients 7 years of age and younger. J Pediatr Gastroenterol Nutr 2014;59:758-62. https://doi.org/10.1097/MPG.0000000000000533
  43. Bramuzzo M, Arrigo S, Romano C, Filardi MC, Lionetti P, Agrusti A, et al. Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study. United European Gastroenterol J 2019;7:759-66. https://doi.org/10.1177/2050640619847592
  44. Ono S, Okano T, Hoshino A, Yanagimachi M, Hamamoto K, Nakazawa Y, et al. Hematopoietic stem cell transplantation for XIAP deficiency in Japan. J Clin Immunol 2017;37:85-91. https://doi.org/10.1007/s10875-016-0348-4
  45. Marsh RA, Rao K, Satwani P, Lehmberg K, Muller I, Li D, et al. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood 2013;121:877-83. https://doi.org/10.1182/blood-2012-06-432500
  46. Lum SH, Hoenig M, Gennery AR, Slatter MA. Conditioning regimens for hematopoietic cell transplantation in primary immunodeficiency. Curr Allergy Asthma Rep 2019;19:52. https://doi.org/10.1007/s11882-019-0883-1
  47. Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis $factor-{\alpha}$ blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010;51:1429-34. https://doi.org/10.1086/657308
  48. Kawai T, Watanabe N, Yokoyama M, Arai K, Oana S, Harayama S, et al. Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous disease. Clin Immunol 2013;147:122-8. https://doi.org/10.1016/j.clim.2013.03.004
  49. Sokol H, Suarez F, Meatchi T, Malamut G, Pocidalo MA, Blanche S, et al. Thalidomide as a treatment for refractory CGD colitis. Am J Gastroenterol 2009;104:1069. https://doi.org/10.1038/ajg.2009.56
  50. de Luca A, Smeekens SP, Casagrande A, Iannitti R, Conway KL, Gresnigt MS, et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci U S A 2014;111:3526-31. https://doi.org/10.1073/pnas.1322831111
  51. Shouval DS, Biswas A, Kang YH, Griffith AE, Konnikova L, Mascanfroni ID, et al. Interleukin $1{\beta}$ mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency. Gastroenterology 2016;151:1100-4. https://doi.org/10.1053/j.gastro.2016.08.055
  52. Galeotti C, Meinzer U, Quartier P, Rossi-Semerano L, Bader-Meunier B, Pillet P, et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford) 2012;51:1855-9. https://doi.org/10.1093/rheumatology/kes097
  53. Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al. Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 2015;349:436-40. https://doi.org/10.1126/science.aaa1663
  54. Dipasquale V, Romano C. Vaccination strategies in pediatric inflammatory bowel disease. Vaccine 2017;35:6070-5. https://doi.org/10.1016/j.vaccine.2017.09.031
  55. Kamei K, Miyairi I, Ishikura K, Ogura M, Shoji K, Funaki T, et al. Prospective study of live attenuated vaccines for patients with nephrotic syndrome receiving immunosuppressive agents. J Pediatr 2018;196:217-22.e1. https://doi.org/10.1016/j.jpeds.2017.12.061
  56. Maxwell EC, Dawany N, Baldassano RN, Mamula P, Mattei P, Albenberg L, et al. Diverting ileostomy for the treatment of severe, refractory, pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2017;65:299-305. https://doi.org/10.1097/MPG.0000000000001498
  57. Kammermeier J, Dziubak R, Pescarin M, Drury S, Godwin H, Reeve K, et al. Phenotypic and genotypic characterisation of inflammatory bowel disease presenting before the age of 2 years. J Crohn's Colitis 2017;11:60-9. https://doi.org/10.1093/ecco-jcc/jjw118